DIFFERENT DOSING OF INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION BECAUSE OF PATHOLOGIC MYOPIA

Abstract

To compare the visual outcomes and retreatment rate of single injection of intravitreal bevacizumab followed by pro re nata (PRN) treatment and three monthly injections of intravitreal bevacizumab followed by PRN treatment for myopic choroidal neovascularization. Thirty-one consecutive eyes of 31 patients with myopic choroidal neovascularization were retrospectively evaluated. Nineteen eyes were treated with a single injection + PRN and 12 eyes with 3 monthly injections + PRN. The best-corrected visual acuity 12 months after the initial injection, logarithm of the minimum angle of resolution gain from baseline, recurrence rate, and number of injections were statistically compared. Baseline best-corrected visual acuity (logarithm of the minimal angle of resolution) was 0.42 ± 0.31 in the single injection + PRN group and 0.47 ± 0.29 in the 3 monthly injections + PRN group (P = 0.64). The best-corrected visual acuity improved significantly at 3, 6, and 12 months in both groups (P < 0.05 at each time point). Mean logarithm of the minimal angle of resolution gain at 3, 6, and 12 months did not differ significantly between groups. The single injection + PRN group required significantly fewer intravitreal bevacizumab treatments (P = 0.005). The rate of recurrence and choroidal neovascularization persistence did not differ significantly between groups. Compared with 3 monthly injections followed by PRN, single injection followed by PRN for myopic choroidal neovascularization required fewer injections and produced a similar visual outcome over 12 months.